Skip to main content

Clinical trial DALY 2-EU

A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation (M-2020-371)

Cancers
Organ Non-Hodgkin lymphoma
Trial status Trial open for recruitment
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor Miltenyi Biomedicine GmbH
EudraCT Identifier 2020-003908-14
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04844866
Inclusion criteria - Histologically proven DLBCL and associated subtypes- Relapsed or refractory disease after first-line chemoimmunotherapy- Participants must have received adequate first-line therapy containing at least the combination of an anthracycline-based regime
Last update